CL2022003400A1 - Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette - Google Patents
Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de touretteInfo
- Publication number
- CL2022003400A1 CL2022003400A1 CL2022003400A CL2022003400A CL2022003400A1 CL 2022003400 A1 CL2022003400 A1 CL 2022003400A1 CL 2022003400 A CL2022003400 A CL 2022003400A CL 2022003400 A CL2022003400 A CL 2022003400A CL 2022003400 A1 CL2022003400 A1 CL 2022003400A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- phosphodiesterase inhibitor
- tourette syndrome
- syndrome
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035310P | 2020-06-05 | 2020-06-05 | |
| US202163160302P | 2021-03-12 | 2021-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003400A1 true CL2022003400A1 (es) | 2023-07-28 |
Family
ID=76325557
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003400A CL2022003400A1 (es) | 2020-06-05 | 2022-12-01 | Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette |
| CL2025002636A CL2025002636A1 (es) | 2020-06-05 | 2025-08-29 | Uso inhibidor de pde10 para tratamiento del síndrome de tourette (divisional de solicitud no. 202203400) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025002636A CL2025002636A1 (es) | 2020-06-05 | 2025-08-29 | Uso inhibidor de pde10 para tratamiento del síndrome de tourette (divisional de solicitud no. 202203400) |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11883385B2 (https=) |
| EP (1) | EP4161526A1 (https=) |
| JP (2) | JP7748974B2 (https=) |
| KR (2) | KR20250171459A (https=) |
| CN (2) | CN116137811B (https=) |
| AU (1) | AU2021285225A1 (https=) |
| BR (1) | BR112022024751A2 (https=) |
| CA (1) | CA3180793A1 (https=) |
| CL (2) | CL2022003400A1 (https=) |
| IL (1) | IL298713A (https=) |
| MX (1) | MX2022015400A (https=) |
| PH (1) | PH12023550007A1 (https=) |
| WO (1) | WO2021245280A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12544364B2 (en) * | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| WO2022162193A1 (en) * | 2021-01-28 | 2022-08-04 | Noema Pharma Ag | Methods for the treatment of childhood-onset fluency disorder |
| WO2026068583A1 (en) * | 2024-09-25 | 2026-04-02 | Noema Pharma Ag | Use of phosphodiesterase 10 inhibitor gemlapodect for weight loss |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| EP1723134A2 (en) * | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| US7786139B2 (en) * | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| US8349824B2 (en) * | 2010-12-07 | 2013-01-08 | Hoffmann-La Roche Inc. | Triazolopyridine compounds |
| BR112014004310B8 (pt) * | 2011-08-25 | 2023-04-18 | Merck Sharp & Dohme | Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto |
| PL3919060T3 (pl) * | 2012-07-12 | 2025-10-20 | Emalex Biosciences, Inc. | Ekopipam do leczenia zespołu tourette'a |
| NZ708593A (en) * | 2013-02-27 | 2018-01-26 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
| MY169128A (en) * | 2013-04-30 | 2019-02-18 | Hoffmann La Roche | Pd-catalyzed coupling of pyrazole amides |
-
2021
- 2021-06-04 CN CN202180057821.7A patent/CN116137811B/zh active Active
- 2021-06-04 IL IL298713A patent/IL298713A/en unknown
- 2021-06-04 MX MX2022015400A patent/MX2022015400A/es unknown
- 2021-06-04 CA CA3180793A patent/CA3180793A1/en active Pending
- 2021-06-04 JP JP2022574676A patent/JP7748974B2/ja active Active
- 2021-06-04 WO PCT/EP2021/065074 patent/WO2021245280A1/en not_active Ceased
- 2021-06-04 KR KR1020257039481A patent/KR20250171459A/ko active Pending
- 2021-06-04 EP EP21730917.8A patent/EP4161526A1/en active Pending
- 2021-06-04 AU AU2021285225A patent/AU2021285225A1/en active Pending
- 2021-06-04 BR BR112022024751A patent/BR112022024751A2/pt unknown
- 2021-06-04 PH PH1/2023/550007A patent/PH12023550007A1/en unknown
- 2021-06-04 KR KR1020237000369A patent/KR102892626B1/ko active Active
- 2021-06-04 CN CN202511962745.0A patent/CN121891333A/zh active Pending
-
2022
- 2022-12-01 CL CL2022003400A patent/CL2022003400A1/es unknown
- 2022-12-02 US US18/061,206 patent/US11883385B2/en active Active
-
2025
- 2025-08-29 CL CL2025002636A patent/CL2025002636A1/es unknown
- 2025-09-22 JP JP2025156736A patent/JP2025183391A/ja active Pending
- 2025-11-25 US US19/401,292 patent/US20260076950A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116137811A (zh) | 2023-05-19 |
| KR102892626B1 (ko) | 2025-11-28 |
| CA3180793A1 (en) | 2021-12-09 |
| CN116137811B (zh) | 2026-01-09 |
| BR112022024751A2 (pt) | 2023-03-07 |
| CN121891333A (zh) | 2026-04-21 |
| IL298713A (en) | 2023-02-01 |
| US20260076950A1 (en) | 2026-03-19 |
| JP2025183391A (ja) | 2025-12-16 |
| US11883385B2 (en) | 2024-01-30 |
| AU2021285225A1 (en) | 2023-01-19 |
| WO2021245280A1 (en) | 2021-12-09 |
| JP7748974B2 (ja) | 2025-10-03 |
| EP4161526A1 (en) | 2023-04-12 |
| MX2022015400A (es) | 2023-03-16 |
| WO2021245280A9 (en) | 2022-01-27 |
| CL2025002636A1 (es) | 2025-11-28 |
| US20230149372A1 (en) | 2023-05-18 |
| PH12023550007A1 (en) | 2024-03-11 |
| JP2023528896A (ja) | 2023-07-06 |
| KR20230040978A (ko) | 2023-03-23 |
| KR20250171459A (ko) | 2025-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003400A1 (es) | Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette | |
| CL2024000373A1 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CL2022002919A1 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| UY30004A1 (es) | Metodos y kits para dosificar nucléosidos antivirales beta-d-2´, 3´-didehidro-2´, 3´- dideoxi-5-fluorocitidina | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| DOP2022000031A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CR20250160A (es) | Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido) carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| CL2024000115A1 (es) | Anticuerpos anti-hla-g | |
| MX2023015121A (es) | Metodos de uso de inhibidores de aldosterona sintasa. | |
| MX2025002228A (es) | Metodos para el tratamiento o la profilaxis de la endometriosis | |
| CL2023002192A1 (es) | Métodos para el tratamiento del trastorno del habla en niños | |
| PE20240822A1 (es) | Inhibidores de vmat2 y metodos de uso | |
| MX2021011979A (es) | Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa. | |
| BR112012031289A2 (pt) | novos derivados 1,4-diazepanos, inibidores de pde-5 |